455 related articles for article (PubMed ID: 23080489)
1. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
[TBL] [Abstract][Full Text] [Related]
2. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
6. HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil.
de Souza Cavalcanti J; de Paula Ferreira JL; Vidal JE; de Souza Guimarães PM; Moreira DH; de Macedo Brigido LF;
Int J Antimicrob Agents; 2014 Mar; 43(3):287-91. PubMed ID: 24359837
[TBL] [Abstract][Full Text] [Related]
7. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
[TBL] [Abstract][Full Text] [Related]
8. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
12. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
[TBL] [Abstract][Full Text] [Related]
14. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
15. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
Ferns RB; Kirk S; Bennett J; Cook PM; Williams I; Edwards S; Pillay D
AIDS; 2009 Oct; 23(16):2159-64. PubMed ID: 19571721
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
[TBL] [Abstract][Full Text] [Related]
18. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
[TBL] [Abstract][Full Text] [Related]
20. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
